Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $247,500.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 2,500 shares of Kymera Therapeutics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $99.00, for a total value of $247,500.00. Following the sale, the insider owned 50,195 shares of the company’s stock, valued at approximately $4,969,305. This trade represents a 4.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Noah Goodman also recently made the following trade(s):

• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Up 10.0%

Shares of NASDAQ KYMR traded up $9.02 during trading hours on Monday, hitting $99.45. 2,891,041 shares of the stock were exchanged, compared to its average volume of 688,878. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $105.00. The firm has a fifty day moving average price of $83.16 and a 200-day moving average price of $81.06. The company has a market cap of $8.18 billion, a PE ratio of -27.86 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. UBS Group lifted their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Royal Bank Of Canada reiterated an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Citigroup boosted their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Stephens increased their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $117.14.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $63,000. Osaic Holdings Inc. grew its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Kymera Therapeutics by 56.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after acquiring an additional 463 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.